Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1NET 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 29Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5olaparib 4lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4copper dotatate CU-64 3atezolizumab 3Temozolomide 3Ga(III)-DOTATOC 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
68Ga-FAPI × NET × 1 year × Clear all
NCT07132645 2025-09-23

An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡